TP53 and head and neck squamous cell carcinoma: A meta-analysis examining patients with recurrent HNSCC who received adenovirus–p53 gene therapy revealed that those who responded to the treatment exhibited low levels of p53 staining and lacked TP53 missense mutations [174], suggesting that high mutp53 levels may limit efficacy.